Altimmune (ALT)
(Delayed Data from NSDQ)
$6.39 USD
-0.11 (-1.69%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $6.42 +0.03 (0.47%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Altimmune, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 198 | 185 | 190 | 216 | 37 |
Receivables | 5 | 3 | 6 | 12 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 5 | 8 | 2 | 0 |
Total Current Assets | 210 | 193 | 204 | 230 | 39 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 12 | 12 | 13 | 13 |
Deposits & Other Assets | 0 | 1 | 1 | 0 | 0 |
Total Assets | 211 | 207 | 219 | 245 | 54 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 2 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 12 | 10 | 11 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 6 | 0 | 0 |
Total Current Liabilities | 12 | 17 | 18 | 12 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 5 | 1 | 7 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 17 | 22 | 20 | 19 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 665 | 568 | 497 | 417 | 188 |
Retained Earnings | -466 | -378 | -293 | -186 | -137 |
Other Equity | -5 | -5 | -5 | -5 | -5 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 194 | 185 | 199 | 226 | 46 |
Total Liabilities & Shareholder's Equity | 211 | 207 | 219 | 245 | 54 |
Total Common Equity | 194 | 185 | 199 | 226 | 46 |
Shares Outstanding | 70.60 | 49.10 | 39.70 | 33.00 | 15.30 |
Book Value Per Share | 2.75 | 3.77 | 5.02 | 6.84 | 2.98 |
Fiscal Year End for Altimmune, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 165 | 182 | 198 | 141 | 160 |
Receivables | 3 | 3 | 5 | 5 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 7 | 8 | 6 |
Total Current Assets | 171 | 188 | 210 | 153 | 170 |
Net Property & Equipment | 0 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 12 | 12 |
Deposits & Other Assets | 2 | 0 | 0 | 0 | 0 |
Total Assets | 173 | 188 | 211 | 167 | 183 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 2 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 8 | 10 | 9 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 15 | 11 | 12 | 12 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 4 | 4 | 4 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 21 | 15 | 17 | 16 | 16 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 673 | 669 | 665 | 590 | 587 |
Retained Earnings | -515 | -491 | -466 | -435 | -414 |
Other Equity | -5 | -5 | -5 | -5 | -5 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 153 | 173 | 194 | 150 | 168 |
Total Liabilities & Shareholder's Equity | 173 | 188 | 211 | 167 | 183 |
Total Common Equity | 153 | 173 | 194 | 150 | 168 |
Shares Outstanding | 70.90 | 70.90 | 70.60 | 52.60 | 49.20 |
Book Value Per Share | 2.15 | 2.44 | 2.75 | 2.86 | 3.41 |